Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
about
Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskStandards of medical care in diabetes--2012Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Origin and therapy for hypertriglyceridaemia in type 2 diabetesResidual macrovascular risk in 2013: what have we learned?Role of bile acid sequestrants in the treatment of type 2 diabetesFenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemiaLipid-related markers and cardiovascular disease prediction.Standards of medical care in diabetes--2013Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Spectroscopy in Medically-Underserved HIV-Infected Persons.Standards of medical care in diabetes--2010.Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).Triglycerides and cardiovascular risk.Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemiaAtherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes--a systematic review.New frontiers in the treatment of diabetic dyslipidemiaCritical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemiaEffect of colesevelam HCl monotherapy on lipid particles in type 2 diabetes mellitus.To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant CholesterolColesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.Characterization of lipid profile by nuclear magnetic resonance spectroscopy (1H NMR) of metabolically healthy obese women after weight loss with Mediterranean diet and physical exercise.Update on lipids and C-reactive protein in acute and chronic coronary heart disease.Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)Incidence of cardiovascular events after kidney transplantation and cardiovascular risk scores: study protocolAtherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementPrevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID).Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics StudyLow high-density lipoprotein cholesterol: current status and future strategies for management.Lipoprotein particle concentrations in children and adults following Kawasaki disease.Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapyStandards of medical care in diabetes--2011.Effectiveness of treat-to-target strategy for LDL-cholesterol control in type 2 diabetes: post-hoc analysis of data from the MIND.IT study.
P2860
Q24626884-0700E549-8873-4891-8110-E87EF2EF5391Q24632533-9220F4A1-D34A-40ED-A661-24115A6B1A62Q26740253-C824786E-99B8-41FB-B0C4-4E2FE5C06FAAQ26824004-1E4D6B9A-D526-4810-A380-89771BC61994Q26996039-DD4CADBF-FE35-4B7B-B446-AC8DD81F2A69Q28236411-98C03772-4534-4B7F-9623-1271E3027930Q28284661-CC77FF8E-51BD-4E14-849B-B60702A396A1Q28654304-78EB367F-533C-42B2-9111-1987472638CAQ29620309-64F21D20-BB88-43F1-811E-FF2C8239EF90Q30585937-3AC46C3F-4FA9-4065-AE88-AF24857624C1Q33554046-921B751C-A7FC-4886-B0F7-662AF40A8367Q33554238-CCA6029E-2DCB-4E53-BE98-A529DD0C0EC3Q33559274-2E8794B1-2F1B-4D8B-9910-3BC14EF21386Q33604888-E0017253-C27C-4766-9E14-54A6E20F3DB2Q33621905-999DB4E1-C1D7-4DB9-8EDF-88C15E30B7DCQ33654016-F13D94BD-FC7E-4A28-A12F-7D82466C8927Q33751975-28D58882-27C3-46FA-83EB-76615A484CC3Q33776194-5FF2B279-7CEC-4FD8-B904-8AFF67F70B96Q33776214-73CA3DB0-AA9C-4231-894F-AE97D46F91E6Q33776236-53643A42-A410-46E9-B08B-F49B15C873D4Q33802196-B56BD9D1-34DF-4B11-8804-44B599256CF0Q33804581-E92BA5D8-40D5-4777-BC25-75688DCB232AQ33818877-7ADE89FC-6EEB-4A3E-9219-5F7AB6A87E2FQ33820018-DDF1F411-F7BE-4B8A-B1B2-3EFD99BC76F8Q33824019-27B03F3B-5F01-4FE5-BC33-7E531D36294AQ33848771-5FF83BEB-2736-4544-A0FD-952C439EF487Q33854022-59379482-6249-43C4-B7DF-48F7238ABA8EQ33885701-D8434ABA-5EC9-4F1C-A11F-37AE627DDEFBQ33887918-CDACE221-F383-45FA-8453-F1305A2BD113Q33921592-2E365FCE-C44D-41A7-BD2D-02BD8934F2EBQ33922262-8CB27CE9-A1B1-491E-ABD5-6F9864D6CE7CQ34139042-1FC14059-372A-4B6B-9EA0-4B6E69341DBFQ34181381-CF154E58-E7A0-4D3C-AFCE-62C7D59705ACQ34229002-BB6A5912-A647-4217-A212-D78E39DFE4A8Q34291764-50E61466-0586-4C2E-BDB6-2436686B78AAQ34334846-ED75EF04-8657-4BD2-BC77-DE70B201BDA3Q34395917-EFF895FE-CF4F-479C-8D54-D7B312D66D7EQ34417470-5B4CE11D-F6C0-4F28-82EE-53343D432A8DQ34425055-86CC354C-5ECC-4B7C-8686-7CFFFE535CB8Q34475329-07B50C1C-1BE8-4502-9588-D68EF6675095
P2860
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@ast
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@en
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@nl
type
label
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@ast
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@en
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@nl
prefLabel
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@ast
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@en
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@nl
P2093
P50
P356
P1433
P1476
Lipoprotein management in pati ...... lege of Cardiology Foundation.
@en
P2093
Barbara V Howard
Curt D Furberg
John D Brunzell
Michael Davidson
Ronald B Goldberg
P304
P356
10.2337/DC08-9018
P407
P50
P577
2008-04-01T00:00:00Z